Alcidion Group Ltd (ASX: ALC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Alcidion Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$183.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
1.27 billion
Earnings per share
-0.006
Dividend per share
N/A
Year To Date Return
-49.09%
Earnings Yield
N/A
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Alcidion Group Ltd (ASX: ALC)
Latest News
Small Cap Shares
3 exciting small cap ASX shares to watch
Broker Notes
4 fallen ASX shares that are still awesome businesses: expert
Small Cap Shares
3 growing small cap ASX shares going places
Small Cap Shares
4 small cap ASX shares for your watchlist
Small Cap Shares
3 exciting small cap ASX shares to watch
Small Cap Shares
3 exciting small cap ASX shares rated as buys
Best Shares
Top ASX shares to buy in 2022
Broker Notes
3 ASX shares now bargains after a nightmare November
ALC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Alcidion Group Ltd
Alcidion Group Ltd (ASX: ALC) is a Melbourne-based company focused on developing and licensing a range of software products for use in the healthcare sector. The company’s own brands include Miya, Patientrack and Smartpage and it also distributes selected products developed by its partner organisations.
Alcidion has offices and operations throughout Australia as well as in New Zealand and the United Kingdom. Its technology platforms are designed to improve the accuracy, efficiency and functionality of the often myriad of disconnected IT systems used in healthcare environments. As at October 2020, the company’s platforms are utilised by more than 65,000 users across over 300 hospitals in Australia, New Zealand and the UK.
According to Alcidion, the company is committed to continually innovating in its quest to support clinicians and improve the management and workflow of healthcare operations. Alcidion first listed on the ASX in mid-2011. The Alcidion share price has not been an overly strong performer and, despite reaching as high as 30 cents in late 2019, has spent much of the time since listing trading around or below 10 cents.
ALC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 May 2022 | $0.14 | $0.00 | 0.00% | 1,274,017 | $0.15 | $0.15 | $0.14 |
| 12 May 2022 | $0.15 | $0.00 | 0.00% | 1,049,597 | $0.15 | $0.15 | $0.15 |
| 11 May 2022 | $0.15 | $-0.01 | -6.67% | 2,249,212 | $0.15 | $0.16 | $0.14 |
| 10 May 2022 | $0.15 | $-0.01 | -6.45% | 2,587,522 | $0.15 | $0.16 | $0.14 |
| 09 May 2022 | $0.16 | $-0.01 | -6.25% | 1,148,775 | $0.16 | $0.16 | $0.15 |
| 06 May 2022 | $0.16 | $-0.01 | -6.06% | 1,221,908 | $0.17 | $0.17 | $0.16 |
| 05 May 2022 | $0.17 | $-0.01 | -5.88% | 1,248,101 | $0.17 | $0.17 | $0.17 |
| 04 May 2022 | $0.17 | $0.00 | 0.00% | 794,546 | $0.18 | $0.18 | $0.17 |
| 03 May 2022 | $0.17 | $-0.01 | -5.56% | 662,157 | $0.18 | $0.18 | $0.17 |
| 02 May 2022 | $0.18 | $0.01 | 5.71% | 1,443,343 | $0.18 | $0.18 | $0.17 |
| 29 Apr 2022 | $0.18 | $-0.01 | -5.56% | 2,343,857 | $0.19 | $0.19 | $0.17 |
| 28 Apr 2022 | $0.18 | $-0.01 | -5.41% | 2,105,034 | $0.19 | $0.19 | $0.18 |
| 27 Apr 2022 | $0.19 | $-0.01 | -5.13% | 2,034,030 | $0.20 | $0.20 | $0.19 |
| 26 Apr 2022 | $0.20 | $-0.01 | -5.00% | 404,123 | $0.20 | $0.20 | $0.20 |
| 22 Apr 2022 | $0.20 | $-0.01 | -4.76% | 1,322,682 | $0.21 | $0.21 | $0.20 |
| 21 Apr 2022 | $0.21 | $0.01 | 4.88% | 829,904 | $0.21 | $0.21 | $0.20 |
| 20 Apr 2022 | $0.21 | $0.00 | 0.00% | 1,032,030 | $0.21 | $0.21 | $0.20 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Jan 2022 | Rebecca Wilson | Issued | 88 | $36,141 |
Rights issue.
|
| 04 Jan 2022 | Rebecca Wilson | Issued | 55 | $36,141 |
Rights issue.
|
| 04 Jan 2022 | Simon Chamberlain | Issued | 28 | $7,024 |
Rights issue.
|
| 04 Jan 2022 | Daniel Sharp | Issued | 28 | $7,143 |
Rights issue.
|
| 23 Dec 2021 | Simon Chamberlain | Buy | 194 | $49,524 |
On-market trade.
|
| 23 Dec 2021 | Victoria Weekes | Buy | 160 | $41,587 |
On-market trade.
|
| 15 Dec 2021 | Katrina (Kate) Doyle (Quirke) | Issued | 1 | $250,000 |
Rights issue.
|
| 17 May 2021 | Katrina (Kate) Doyle (Quirke) | Sell | 11 | $3,903,632 |
On-market trade. As per announcement on 18/05/2021.
|
| 17 May 2021 | Simon Chamberlain | Buy | 295 | $100,300 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Rebecca Wilson | Non-Executive DirectorNon-Executive Chairman | Jul 2017 |
Ms Wilson has more than 20 years experience working within the healthcare, technology and life science sectors providing advice on stakeholder communications, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She advises boards and executive teams on investor relations and commercial strategies and has experience in transactions, including more than 60 IPOs, M&A transactions, and hundreds of capital raisings. Rebecca is an Executive Director of consulting firm WE Worldwide. She is a member and graduate of the Australian Institute of Company Directors (AICD).
|
| Mr Simon Chamberlain | Non-Executive Director | Jul 2019 |
Mr has more than 20 years' experience in executive roles at companies including Experian, Medibank Private, Qantas and MedAdvisor and in his current role, leading strategy and marketing at the high growth residential services business, Detector Inspector. Simon led Qantas' entrance into the online hotels business, establishing a profitable, high growth new division. At Medibank, Simon had responsibility across customer channels, data and customer experience. Gaining a better understanding of the complex challenges facing the wider health system led to Simon's role leading strategy for MedAdvisor, where he supported the global expansion of its health technology business.
|
| Professor Malcolm Pradhan | Executive Director | Feb 2016 |
Professor Pradhan has over 25 years of experience in Medical Informatics. Malcolm has been a advocate for interoperability, and a sustainable health care system using smart data-driven IT systems that improve patient safety, reduce clinician workloads and support new models of care.
|
| Ms Victoria Weekes | Non-Executive Director | Sep 2021 |
Ms Weekes has experience in the banking and finance sectors. Ms Weekes was the immediate past Acting Chair of the Sydney Local Health District Board and is an experienced Non-Executive Director with current appointments including FINSIA, NSW Treasury Audit and Risk, and St George Community Housing. Ms Weekes will Chair Alcidion's Risk Committee from 01/09/2021.
|
| Ms Katrina (Kate) Elizabeth Doyle (Quirke) | Chief Executive OfficerExecutive DirectorManaging Director | Jul 2018 |
Ms Quirke has more than 25 years of experience in the healthcare information technology sector. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, New Zealand and South East Asia. Kate's background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide.
|
| Mr Daniel Sharp | Non-Executive Director | Sep 2021 |
Mr Sharp has more than 30 years' experience in capital markets globally, advising the boards of technology and healthcare-based organizations, and with a network of institutional and private wealth investors globally. He is an immediate past Executive Director of Canaccord Genuity and previously held executive senior corporate banking roles with Shaw and Partners and Lodge Partners.
|
| Ms Melanie Jaye Leydin | Company Secretary | Mar 2019 |
-
|
| Matthew Gepp | Chief Financial Officer |
-
|
|
| Colin McKinnon | Chief Operating Officer |
-
|
|
| Melanie Jaye Leydin | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malcolm Pradhan | 134,582,403 | 12.84% |
| Mr Raymond Blight | 95,828,781 | 9.14% |
| J P Morgan Nominees Australia Pty Limited | 55,835,785 | 5.33% |
| Isle of Wight Pty Limited | 49,405,192 | 4.71% |
| Caledonia Nominees Pty Limited | 35,976,377 | 3.43% |
| Mrs Katrina Doyle | 27,793,199 | 2.65% |
| Rewmicman Pty Limited | 26,026,606 | 2.48% |
| Rangiora-London Pty Limited | 25,102,251 | 2.40% |
| Sandhurst Trustees Limited <JMFG CONSOL A/C> | 24,453,360 | 2.33% |
| MNMD Pty Limited | 18,668,086 | 1.78% |
| Citicorp Nominees Pty Limited | 18,102,425 | 1.73% |
| HSBC Custody Nominees (Australia) Limited | 16,552,966 | 1.58% |
| Mr Colin MacKinnon + Mrs Maree MacKinnon | 9,676,550 | 0.92% |
| National Nominees Limited | 9,618,072 | 0.92% |
| Sandhurst Trustees Limited <CYAN C3G FUND A/C> | 7,819,114 | 0.75% |
| Rewmicman Pty Limited (i) | 7,533,835 | 0.72% |
| BNP Paribas Noms Pty Ltd | 6,233,372 | 0.59% |
| Emerald Shares Pty Limited | 6,118,750 | 0.58% |
| Cs Third Nominees Pty Limited | 5,680,121 | 0.54% |
| Mr Vivek Ramakrishnan + Miss Nisha Srinivasan | 5,593,121 | 0.53% |